Back to discover
Drug

Gabapentin

Approved · FDA
ClassVoltage-gated calcium channel modulatorEmerging researchLate-stage developmentRising momentum
Also known as 1-(Aminomethyl)cyclohexaneacetic acid, Gabarone, Gralise, Horizant+6 more

1-(Aminomethyl)cyclohexaneacetic acid, Gabarone, Gralise, Horizant, Neurontin, Relgaabi, Gabapentina, Gabapentine, Gabapentino, Gabapentinum.

3
Research papers
16
Active clinical trials
26
Protein targets
27
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Gabapentin to Reduce Alcohol and Improve Viral Load Suppression - Promoting "Treatment as Prevention"

Clinical trial2026-07-01Results expected Q4 2026 · ClinicalTrials.gov

Approval: GABAPENTIN (ANDA203611)

Regulatory2026-06-23FDA

Nonopioid Pain Control Regimen After Arthroscopic Hip Procedures

Clinical trial2026-06-03Results posted · ClinicalTrials.gov

A proof-of-concept randomized controlled study of gabapentin: effects on cannabis use, withdrawal and executive function deficits in cannabis-dependent adults.

Research2012-02-29Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Gabapentin
Aliases & brands
1-(Aminomethyl)cyclohexaneacetic acidGabaroneGraliseHorizantNeurontinRelgaabiGabapentinaGabapentineGabapentinoGabapentinum
RxNorm CUI
25480
ChEMBL ID
CHEMBL940
ATC codes
N02BF01
UNII
6CW7F3G59X
Primary mechanism
Voltage-gated calcium channel modulator
Regulatory jurisdictions
mhrafda

Pharmacology & targets

26 targets

Known molecular targets and mechanisms supported by curated pharmacology databases.

MODULATORVoltage-gated calcium channel modulator
MODULATORVoltage-gated calcium channel modulator
MODULATORVoltage-gated calcium channel modulator
MODULATORVoltage-gated calcium channel modulator
MODULATORVoltage-gated calcium channel modulator
MODULATORVoltage-gated calcium channel modulator
MODULATORVoltage-gated calcium channel modulator
MODULATORVoltage-gated calcium channel modulator
MODULATORVoltage-gated calcium channel modulator
MODULATORVoltage-gated calcium channel modulator
MODULATORVoltage-gated calcium channel modulator
MODULATORVoltage-gated calcium channel modulator
MODULATORVoltage-gated calcium channel modulator
MODULATORVoltage-gated calcium channel modulator
MODULATORVoltage-gated calcium channel modulator
MODULATORVoltage-gated calcium channel modulator
MODULATORVoltage-gated calcium channel modulator
MODULATORVoltage-gated calcium channel modulator
MODULATORVoltage-gated calcium channel modulator
MODULATORVoltage-gated calcium channel modulator
MODULATORVoltage-gated calcium channel modulator
MODULATORVoltage-gated calcium channel modulator
MODULATORVoltage-gated calcium channel modulator
MODULATORVoltage-gated calcium channel modulator
MODULATORVoltage-gated calcium channel modulator
MODULATORVoltage-gated calcium channel modulator

Regulatory timeline

27 events

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval
2006-01-24
Latest approval
2026-06-23
Authorities
FDA · MHRA
Total events
27
fdaU.S. Food and Drug Administration· 26 events
2026-07-22Label change
Label change: GABAPENTIN (ANDA217995)
Evidence ↗
2026-07-17Label change
Label change: GABAPENTIN (ANDA203934)
Evidence ↗
2026-07-16Label change
Label change: GABAPENTIN (ANDA075428)
Evidence ↗
mhraMedicines and Healthcare products Regulatory Agency· 1 event
2017-10-26Safety communicationSafety
Drug Safety Update: Gabapentin (Neurontin): risk of severe respiratory depression
Evidence ↗

Data from the U.S. Food and Drug Administration (U.S. Food and Drug Administration), public domain (CC0).

Contains public sector information from the Medicines and Healthcare products Regulatory Agency (MHRA) licensed under the Open Government Licence (OGL v3).

Clinical trials

189 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
189
registered trials across all phases
LATEST COMPLETION 2026
16
Active studies
13
Recruiting
148
Late-stage (III+)
122
Completed
51
Discontinued
PHASE DISTRIBUTIONn = 189
Early Phase 16Phase 14Phase 1 / 25Phase 226Phase 2 / 313Phase 333Phase 457Phase N / A45

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Recent completions

Trials that read out recently, adding to the completed evidence base.

Research activity

3 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
20062014
Major research themes1
Survivors1
Journals, researchers & institutions
Top journals
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology1
  • Neurology1
  • Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology1
Leading researchers
  • Adusumalli M1
  • Ames C1
  • Bak K1
  • Begovic A1
  • Bleeker J1
  • Buffkins K1
  • Cavaletti G1
  • Chauhan C1
Leading institutions
free-text, unnormalised
  • Columbia University Medical Center1
  • The Scripps Research Institute1
  • University of California1

Related drugs

5 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Studied across 3 of the same disease areas as Gabapentin in the shared literature.

3 shared diseases1 shared paper

Studied across 3 of the same disease areas as Gabapentin in the shared literature.

3 shared diseases1 shared paper

Studied across 3 of the same disease areas as Gabapentin in the shared literature.

3 shared diseases1 shared paper

Studied across 3 of the same disease areas as Gabapentin in the shared literature.

3 shared diseases1 shared paper

Studied across 3 of the same disease areas as Gabapentin in the shared literature.

3 shared diseases1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials
  • Regulatory event sources are credited in the Regulatory Timeline above.